Table of Contents:
Chapter 1. Research Methodology and Scope
- Market Segmentation and Scope
- Regional Coverage
- Objectives
- Research Methodology
Chapter 2. Executive Summary
- Market Landscape
- Market Size & Forecast
- Competitive Landscape
Chapter 3. Erectile Dysfunction Market: By Product Type Trends, Size, and Future Outlook
- By Product Type Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Product Type Definitions, Technology Landscape
- By Product Type Market Drivers
- Product Launches
- Technology Launches
- By Product Type Market Restraints
Chapter 4. Erectile Dysfunction Market: By Distribution Channel Trends, Size, and Future Outlook
- By Distribution Channel Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Distribution Channel Definitions, Technology Landscape
- By Distribution Channel Market Drivers
- Product Launches
- Technology Launches
- By Distribution Channel Market Restraints
Chapter 5. Erectile Dysfunction Market: By End User Trends, Size, and Future Outlook
- By End User Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By End User Definitions, Technology Landscape
- By End User Market Drivers
- Product Launches
- Technology Launches
- By End User Market Restraints
Chapter 6. Erectile Dysfunction Market: By Disease Indication Trends, Size, and Future Outlook
- By Disease Indication Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Disease Indication Definitions, Technology Landscape
- By Disease Indication Market Drivers
- Product Launches
- Technology Launches
- By Disease Indication Market Restraints
Chapter 7. Erectile Dysfunction Market: By Age Group Trends, Size, and Future Outlook
- By Age Group Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Age Group Definitions, Technology Landscape
- By Age Group Market Drivers
- Product Launches
- Technology Launches
- By Age Group Market Restraints
Chapter 8. Erectile Dysfunction Market: By Drug Type Trends, Size, and Future Outlook
- By Drug Type Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Drug Type Definitions, Technology Landscape
- By Drug Type Market Drivers
- Product Launches
- Technology Launches
- By Drug Type Market Restraints
Chapter 9. Erectile Dysfunction Market: Regional Market Trends, Size, and Future Outlook
- North America
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Europe
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Asia Pacific
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Latin America
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Middle East, and Africa
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Trends, Market Size (US$), CAGR (%), and Future Outlook
Chapter 10. Erectile Dysfunction Market: Competitive Landscape
- Pfizer Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Eli Lilly and Company
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Bayer AG
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Allergan plc (acquired by AbbVie Inc.)
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Mylan N.V.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- GlaxoSmithKline plc
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Merck & Co., Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Sanofi S.A.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Novartis AG
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Apricus Biosciences, Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Vivus, Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Aspen Pharmacare Holdings Limited
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Auxilium Pharmaceuticals, Inc. (acquired by Endo International plc)
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Meda AB
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Dong-A Pharmaceutical Co., Ltd.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Petros Pharmaceuticals, Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- NexMed, Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Shionogi & Co., Ltd.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
Research Methodology
- Primary Research
- Secondary Research
- Assumptions
- IDataAcumen Analysis
- Paid Databases
Appendix
- About Us
Frequently Asked Questions
The current market size of the Erectile Dysfunction industry is estimated to be around US$ 3.2 billion.
Increasing prevalence of chronic diseases, aging population, changing lifestyles, growing awareness, availability of new treatment options, advancements in diagnostics, and increasing healthcare expenditure.
High cost of branded treatments, strict regulatory guidelines, social stigma and cultural barriers, side effects of existing treatments, lack of awareness in developing regions, and limited access to healthcare facilities.
The leading component segment in the Erectile Dysfunction Market is oral medications, which offer convenience and efficacy for ED treatment.
Pfizer Inc., Eli Lilly and Company, Bayer AG, Allergan plc (acquired by AbbVie Inc.), Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Merck & Co., Inc., Sanofi S.A., Novartis AG, and Bristol-Myers Squibb Company.
The Global Erectile Dysfunction Market is expected to reach US$ 6.2 Bn in 2031 with a growth rate of 8.6%
Increasing prevalence of chronic diseases, aging population, changing lifestyles, growing awareness, availability of new treatment options, advancements in diagnostics, and increasing healthcare expenditure.